Dr. Alex A. Adjei is presently the chairman of Taussig Cancer Institute at Cleveland Clinic .
Previously was consultant in Medical Oncology at Mayo Clinic and Professor of Oncology in the Mayo College of Medicine. He was is director of the Early Cancer Therapeutics Program across all three Mayo sites,, also director of Global Oncology and the Principal Investigator of the Mayo Phase I and Phase II NCI grants.
Dr Adjei has served on a number of US National Cancer Institute Lung Cancer Committees. He was Vice-Chair of the North Central Cancer Treatment Group and Lung Cancer Committee Chair. He is currently co-chair of the Thoracic Malignancies Steering Committee, and is a member of subcommittee A (reviewing cancer centers) of the National Cancer Institute. He is the Editor-in-Chief of the Journal of Thoracic Oncology. Dr Adjei’s research is focused on experimental therapeutics and clinical drug development.
He received the first ASCO Drug Development Research Professorship (2012-2017), in recognition of his mentorship and his work in cancer drug development. He has authored 236 publications dealing primarily with preclinical pharmacology and phase I trials as well as novel therapeutics/phase II trials of lung cancer.